181 related articles for article (PubMed ID: 25746813)
61. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
[TBL] [Abstract][Full Text] [Related]
62. The Polycomb group protein EZH2 directly controls DNA methylation.
Viré E; Brenner C; Deplus R; Blanchon L; Fraga M; Didelot C; Morey L; Van Eynde A; Bernard D; Vanderwinden JM; Bollen M; Esteller M; Di Croce L; de Launoit Y; Fuks F
Nature; 2006 Feb; 439(7078):871-4. PubMed ID: 16357870
[TBL] [Abstract][Full Text] [Related]
63. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
64. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.
Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A
J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008
[TBL] [Abstract][Full Text] [Related]
65. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Misawa K; Yamaotsu N; Hirono S
J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
[TBL] [Abstract][Full Text] [Related]
66. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
[TBL] [Abstract][Full Text] [Related]
67. Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
O' Donovan DH; Gregson C; Packer MJ; Greenwood R; Pike KG; Kawatkar S; Bloecher A; Robinson J; Read J; Code E; Hsu JH; Shen M; Woods H; Barton P; Fillery S; Williamson B; Rawlins PB; Bagal SK
Bioorg Med Chem Lett; 2021 May; 39():127904. PubMed ID: 33684441
[TBL] [Abstract][Full Text] [Related]
68. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
[TBL] [Abstract][Full Text] [Related]
69. An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.
Bratkowski M; Yang X; Liu X
Sci Rep; 2018 Jun; 8(1):9092. PubMed ID: 29904056
[TBL] [Abstract][Full Text] [Related]
70. Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Zhang Y; Yang H; Li B; Li J; Li H; Shi Q; Li B; Wang Z; Zheng J; Zhang Y; Dong H; Huang X; Wang Y
J Med Chem; 2023 Jun; 66(11):7629-7644. PubMed ID: 37203326
[TBL] [Abstract][Full Text] [Related]
71. Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.
Zhu MR; Du DH; Hu JC; Li LC; Liu JQ; Ding H; Kong XQ; Jiang HL; Chen KX; Luo C
Acta Pharmacol Sin; 2018 Feb; 39(2):302-310. PubMed ID: 28858300
[TBL] [Abstract][Full Text] [Related]
72. Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase.
Lingel A; Sendzik M; Huang Y; Shultz MD; Cantwell J; Dillon MP; Fu X; Fuller J; Gabriel T; Gu J; Jiang X; Li L; Liang F; McKenna M; Qi W; Rao W; Sheng X; Shu W; Sutton J; Taft B; Wang L; Zeng J; Zhang H; Zhang M; Zhao K; Lindvall M; Bussiere DE
J Med Chem; 2017 Jan; 60(1):415-427. PubMed ID: 27992714
[TBL] [Abstract][Full Text] [Related]
73. Design and synthesis of mimics of S-adenosyl-L-homocysteine as potential inhibitors of erythromycin methyltransferases.
Hanessian S; Sgarbi PW
Bioorg Med Chem Lett; 2000 Mar; 10(5):433-7. PubMed ID: 10743942
[TBL] [Abstract][Full Text] [Related]
74. SAH analogs, modified in the aminoacid region, inhibitors of phosphatidyl-ethanolamine methylase activity and 3H-SAH binding to rat brain membranes.
Fonlupt P; Rey C; Pacheco H
Life Sci; 1982 Aug; 31(7):655-9. PubMed ID: 7132571
[TBL] [Abstract][Full Text] [Related]
75. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.
Yu W; Smil D; Li F; Tempel W; Fedorov O; Nguyen KT; Bolshan Y; Al-Awar R; Knapp S; Arrowsmith CH; Vedadi M; Brown PJ; Schapira M
Bioorg Med Chem; 2013 Apr; 21(7):1787-1794. PubMed ID: 23433670
[TBL] [Abstract][Full Text] [Related]
76. Discovery of Inhibitors of DNA Methyltransferase 2, an Epitranscriptomic Modulator and Potential Target for Cancer Treatment.
Schwickert M; Fischer TR; Zimmermann RA; Hoba SN; Meidner JL; Weber M; Weber M; Stark MM; Koch J; Jung N; Kersten C; Windbergs M; Lyko F; Helm M; Schirmeister T
J Med Chem; 2022 Jul; 65(14):9750-9788. PubMed ID: 35849534
[TBL] [Abstract][Full Text] [Related]
77. Inhibition of Human Enhancer of Zeste Homolog 2 with Tambjamine Analogs.
Kotev M; Manuel-Manresa P; Hernando E; Soto-Cerrato V; Orozco M; Quesada R; Pérez-Tomás R; Guallar V
J Chem Inf Model; 2018; 57(8):2089-2098. PubMed ID: 28763207
[TBL] [Abstract][Full Text] [Related]
78. A Solid-Phase Approach to Accessing Bisthioether-Stapled Peptides Resulting in a Potent Inhibitor of PRC2 Catalytic Activity.
Zhang G; Barragan F; Wilson K; Levy N; Herskovits A; Sapozhnikov M; Rodríguez Y; Kelmendi L; Alkasimi H; Korsmo H; Chowdhury M; Gerona-Navarro G
Angew Chem Int Ed Engl; 2018 Dec; 57(52):17073-17078. PubMed ID: 30339297
[TBL] [Abstract][Full Text] [Related]
79. Molecular and cytological evidence of S-adenosyl-L-homocysteine as an innocuous undermethylating agent in vivo.
De Cabo SF; Santos J; Fernández-Piqueras J
Cytogenet Cell Genet; 1995; 71(2):187-92. PubMed ID: 7656594
[TBL] [Abstract][Full Text] [Related]
80. Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).
Kung PP; Bingham P; Brooun A; Collins M; Deng YL; Dinh D; Fan C; Gajiwala KS; Grantner R; Gukasyan HJ; Hu W; Huang B; Kania R; Kephart SE; Krivacic C; Kumpf RA; Khamphavong P; Kraus M; Liu W; Maegley KA; Nguyen L; Ren S; Richter D; Rollins RA; Sach N; Sharma S; Sherrill J; Spangler J; Stewart AE; Sutton S; Uryu S; Verhelle D; Wang H; Wang S; Wythes M; Xin S; Yamazaki S; Zhu H; Zhu J; Zehnder L; Edwards M
J Med Chem; 2018 Feb; 61(3):650-665. PubMed ID: 29211475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
